Old Blood Pressure Drug Reveals Brain Cancer Secret

New Hope from a Decades-Old Heart Medication

Hydralazine and a New Understanding of Its Power We have relied on hydralazine to lower high blood pressure for many decades, yet for most of that time we did not fully grasp how the medicine achieved its effects. Recent research has now clarified several of those mysteries and has unexpectedly connected the drug to the biology of aggressive brain tumors.

By examining how hydralazine behaves in human and mouse cells, investigators from the University of Pennsylvania discovered that the medication blocks an enzyme known as 2-aminoethanethiol dioxygenase, or ADO. This enzyme has also been implicated in the growth of glioblastoma, one of the most dangerous forms of brain cancer, and that link opens new possibilities for treatment.

Why the Discovery Matters Hydralazine was created long before modern target-focused drug design existed, and we have traditionally judged it by the improvements we saw in patients rather than by a detailed molecular map. The new findings help us understand why the drug has remained a first-choice therapy for conditions such as preeclampsia, a hypertensive disorder responsible for roughly 5 to 15 % of maternal deaths around the world.

Physician Kyosuke Shishikura explained that the medication emerged from a period when doctors observed clinical benefits first and only later attempted to explain the biology behind them.

The Role of the ADO Enzyme Researchers now describe ADO as a kind of internal alarm that warns the body when oxygen levels fall. Once activated, the enzyme sets off a cascade that tightens blood vessels by destroying regulators of G,protein signaling, commonly called RGS proteins. Earlier work showed that glioblastoma tumors often contain high amounts of ADO and use it to manufacture a substance called hypotaurine, which helps cancer cells spread, resist stress, and survive longer than they otherwise would. Until this project, scientists had not identified any substance capable of reliably inhibiting ADO.

What Hydralazine Actually Does The team demonstrated that hydralazine effectively quiets the ADO signal. When the enzyme is muted, RGS proteins remain intact, blood vessels relax rather than constrict, and blood pressure falls. In laboratory experiments using human glioblastoma cells, the drug stopped tumor expansion by interfering with this same pathway. These results are only an early step, and we still need clinical trials in people with glioblastoma, yet the evidence suggests we may have uncovered a way to slow tumors that have long resisted therapy.

Implications for Pregnancy and Hypertension This clearer picture also explains why hydralazine works so well in preeclampsia. With a defined mechanism, we can imagine refining the medicine to suit individual patients, reducing unwanted effects while preserving its benefits. Chemist Megan Matthews noted that understanding the molecular action of the drug offers a route toward safer and more selective treatments for pregnancy-related hypertension and could improve outcomes for those at highest risk.

A Platform for Future Medicines The discoveries mean we can begin designing better drugs for both cardiovascular disease and brain cancer by carefully targeting the relevant cellular pathways while protecting healthy tissue. Because hydralazine is already widely prescribed, scientists start with a significant advantage when creating next-generation therapies based on the compound.

Over time we may be able to remove one of the main defenses used by glioblastoma and strengthen the treatments already under development. Matthews reflected on the unusual connection by saying, “It’s rare that an old cardiovascular drug ends up teaching us something new about the brain, but that’s exactly what we’re hoping to find more of, unusual links that could spell new solutions.”

YOUR CALL TO ACTION FOR UNDERSTANDING HYDRALAZINE AND BRAIN CANCER RESEARCH By following credible science updates, supporting clinical research, and discussing treatment options with qualified professionals, we help move these discoveries from the laboratory into real benefits for families affected by hypertension and glioblastoma.

My YouTube Channel: https://www.youtube.com/@MyLongevityExperiment

Study Links:

https://www.science.org/doi/10.1126/sciadv.adx7687

https://www.nature.com/articles/s41420-020-00398-5

https://www.cancerresearchuk.org/about-cancer/brain-tumours/types/glioblastoma

https://penntoday.upenn.edu/news/penn-chemistry-serendipitous-find-leads-lifesaving-discoveries

https://en.wikipedia.org/wiki/Hypotaurine